CN107889992A - 一种预防和治疗痴呆的功能保健饮料 - Google Patents
一种预防和治疗痴呆的功能保健饮料 Download PDFInfo
- Publication number
- CN107889992A CN107889992A CN201711149396.6A CN201711149396A CN107889992A CN 107889992 A CN107889992 A CN 107889992A CN 201711149396 A CN201711149396 A CN 201711149396A CN 107889992 A CN107889992 A CN 107889992A
- Authority
- CN
- China
- Prior art keywords
- vitamin
- functional health
- health beverage
- acid
- preventing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000036541 health Effects 0.000 title claims abstract description 50
- 235000013361 beverage Nutrition 0.000 title claims abstract description 45
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 claims abstract description 50
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 claims abstract description 25
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 claims abstract description 25
- 229940045145 uridine Drugs 0.000 claims abstract description 25
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims abstract description 22
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims abstract description 20
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 18
- 239000000203 mixture Substances 0.000 claims abstract description 17
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims abstract description 16
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 14
- 239000002253 acid Substances 0.000 claims abstract description 14
- 229960001231 choline Drugs 0.000 claims abstract description 14
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 claims abstract description 14
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 claims abstract description 12
- 235000019743 Choline chloride Nutrition 0.000 claims abstract description 12
- 229960003178 choline chloride Drugs 0.000 claims abstract description 12
- SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 claims abstract description 12
- 239000008777 Glycerylphosphorylcholine Substances 0.000 claims abstract description 11
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 claims abstract description 11
- SUHOQUVVVLNYQR-MRVPVSSYSA-N choline alfoscerate Chemical group C[N+](C)(C)CCOP([O-])(=O)OC[C@H](O)CO SUHOQUVVVLNYQR-MRVPVSSYSA-N 0.000 claims abstract description 11
- 235000020669 docosahexaenoic acid Nutrition 0.000 claims abstract description 11
- 229940090949 docosahexaenoic acid Drugs 0.000 claims abstract description 11
- 235000020673 eicosapentaenoic acid Nutrition 0.000 claims abstract description 11
- 229960005135 eicosapentaenoic acid Drugs 0.000 claims abstract description 11
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 claims abstract description 11
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims abstract description 10
- 102100034279 Calcium-binding mitochondrial carrier protein Aralar2 Human genes 0.000 claims abstract description 10
- PGAVKCOVUIYSFO-XVFCMESISA-N UTP Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1N1C(=O)NC(=O)C=C1 PGAVKCOVUIYSFO-XVFCMESISA-N 0.000 claims abstract description 10
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims abstract description 10
- 229930003316 Vitamin D Natural products 0.000 claims abstract description 10
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims abstract description 10
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims abstract description 10
- 229960002685 biotin Drugs 0.000 claims abstract description 10
- 235000020958 biotin Nutrition 0.000 claims abstract description 10
- 239000011616 biotin Substances 0.000 claims abstract description 10
- 108010084210 citrin Proteins 0.000 claims abstract description 10
- ZWAOHEXOSAUJHY-ZIYNGMLESA-N doxifluridine Chemical compound O[C@@H]1[C@H](O)[C@@H](C)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ZWAOHEXOSAUJHY-ZIYNGMLESA-N 0.000 claims abstract description 10
- 229950005454 doxifluridine Drugs 0.000 claims abstract description 10
- 229950010342 uridine triphosphate Drugs 0.000 claims abstract description 10
- PGAVKCOVUIYSFO-UHFFFAOYSA-N uridine-triphosphate Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)OC1N1C(=O)NC(=O)C=C1 PGAVKCOVUIYSFO-UHFFFAOYSA-N 0.000 claims abstract description 10
- 235000019155 vitamin A Nutrition 0.000 claims abstract description 10
- 239000011719 vitamin A Substances 0.000 claims abstract description 10
- 235000019166 vitamin D Nutrition 0.000 claims abstract description 10
- 239000011710 vitamin D Substances 0.000 claims abstract description 10
- 150000003710 vitamin D derivatives Chemical class 0.000 claims abstract description 10
- 229940045997 vitamin a Drugs 0.000 claims abstract description 10
- 229940046008 vitamin d Drugs 0.000 claims abstract description 10
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 claims abstract description 9
- 229930003427 Vitamin E Natural products 0.000 claims abstract description 9
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract description 9
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 9
- 239000011709 vitamin E Substances 0.000 claims abstract description 9
- 229940046009 vitamin E Drugs 0.000 claims abstract description 9
- PFRQBZFETXBLTP-RCIYGOBDSA-N 2-[(2e,6e,10e,14e,18e)-3,7,11,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaen-1-yl]-3-methyl-1,4-dihydronaphthalene-1,4-dione Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)=C(C)C(=O)C2=C1 PFRQBZFETXBLTP-RCIYGOBDSA-N 0.000 claims abstract description 8
- 229930003451 Vitamin B1 Natural products 0.000 claims abstract description 8
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims abstract description 8
- 229960003495 thiamine Drugs 0.000 claims abstract description 8
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims abstract description 8
- 235000010374 vitamin B1 Nutrition 0.000 claims abstract description 8
- 239000011691 vitamin B1 Substances 0.000 claims abstract description 8
- 235000019158 vitamin B6 Nutrition 0.000 claims abstract description 8
- 239000011726 vitamin B6 Substances 0.000 claims abstract description 8
- 229940011671 vitamin b6 Drugs 0.000 claims abstract description 8
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims abstract description 7
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 7
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims abstract description 7
- 229930003779 Vitamin B12 Natural products 0.000 claims abstract description 7
- 229930003471 Vitamin B2 Natural products 0.000 claims abstract description 7
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 7
- 229960002477 riboflavin Drugs 0.000 claims abstract description 7
- 235000019163 vitamin B12 Nutrition 0.000 claims abstract description 7
- 239000011715 vitamin B12 Substances 0.000 claims abstract description 7
- 235000019164 vitamin B2 Nutrition 0.000 claims abstract description 7
- 239000011716 vitamin B2 Substances 0.000 claims abstract description 7
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 7
- 239000011718 vitamin C Substances 0.000 claims abstract description 7
- 239000004480 active ingredient Substances 0.000 claims abstract description 6
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 claims abstract description 5
- 229940013618 stevioside Drugs 0.000 claims abstract description 5
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 claims abstract description 5
- 235000019202 steviosides Nutrition 0.000 claims abstract description 5
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 18
- 206010012289 Dementia Diseases 0.000 claims description 17
- 208000024827 Alzheimer disease Diseases 0.000 claims description 15
- 239000000194 fatty acid Substances 0.000 claims description 13
- 208000010877 cognitive disease Diseases 0.000 claims description 10
- 208000027061 mild cognitive impairment Diseases 0.000 claims description 10
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 9
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 claims description 9
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 9
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims description 9
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 9
- 229910052791 calcium Inorganic materials 0.000 claims description 9
- 239000011575 calcium Substances 0.000 claims description 9
- 229910052742 iron Inorganic materials 0.000 claims description 9
- 229910052750 molybdenum Inorganic materials 0.000 claims description 9
- 239000011733 molybdenum Substances 0.000 claims description 9
- 229910052698 phosphorus Inorganic materials 0.000 claims description 9
- 239000011574 phosphorus Substances 0.000 claims description 9
- 229910052711 selenium Inorganic materials 0.000 claims description 9
- 239000011669 selenium Substances 0.000 claims description 9
- 229910052712 strontium Inorganic materials 0.000 claims description 9
- CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 claims description 9
- 229910052720 vanadium Inorganic materials 0.000 claims description 9
- LEONUFNNVUYDNQ-UHFFFAOYSA-N vanadium atom Chemical compound [V] LEONUFNNVUYDNQ-UHFFFAOYSA-N 0.000 claims description 9
- 239000011701 zinc Substances 0.000 claims description 9
- 229910052725 zinc Inorganic materials 0.000 claims description 9
- 201000004810 Vascular dementia Diseases 0.000 claims description 6
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 claims description 6
- -1 amino-acid salt Chemical class 0.000 claims description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 3
- 229910052799 carbon Inorganic materials 0.000 claims description 3
- 239000003513 alkali Substances 0.000 claims description 2
- 235000019197 fats Nutrition 0.000 claims description 2
- 229930182470 glycoside Natural products 0.000 claims description 2
- 150000002338 glycosides Chemical class 0.000 claims description 2
- 210000002700 urine Anatomy 0.000 claims description 2
- 150000007513 acids Chemical class 0.000 claims 1
- 235000009508 confectionery Nutrition 0.000 claims 1
- YHHSONZFOIEMCP-UHFFFAOYSA-O phosphocholine Chemical compound C[N+](C)(C)CCOP(O)(O)=O YHHSONZFOIEMCP-UHFFFAOYSA-O 0.000 claims 1
- 239000011573 trace mineral Substances 0.000 abstract description 11
- 235000013619 trace mineral Nutrition 0.000 abstract description 11
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 abstract 2
- 235000020660 omega-3 fatty acid Nutrition 0.000 abstract 2
- 229940012843 omega-3 fatty acid Drugs 0.000 abstract 2
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 abstract 1
- 229940088594 vitamin Drugs 0.000 description 14
- 229930003231 vitamin Natural products 0.000 description 14
- 235000013343 vitamin Nutrition 0.000 description 14
- 239000011782 vitamin Substances 0.000 description 14
- 150000003722 vitamin derivatives Chemical class 0.000 description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 201000010099 disease Diseases 0.000 description 10
- 206010039966 Senile dementia Diseases 0.000 description 7
- 230000007423 decrease Effects 0.000 description 4
- 230000002265 prevention Effects 0.000 description 3
- 150000001336 alkenes Chemical class 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000008451 emotion Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 206010003694 Atrophy Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000003930 cognitive ability Effects 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- JCHMFMSWRWHRFI-HMMYKYKNSA-N ethyl (2e)-2-[(2,5-dichlorophenyl)hydrazinylidene]-2-(2,6-dimethylmorpholin-4-yl)acetate Chemical compound C1C(C)OC(C)CN1/C(C(=O)OCC)=N/NC1=CC(Cl)=CC=C1Cl JCHMFMSWRWHRFI-HMMYKYKNSA-N 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 230000015654 memory Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000032696 parturition Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000006403 short-term memory Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
- A23L33/155—Vitamins A or D
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Non-Alcoholic Beverages (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
一种预防和治疗痴呆的功能保健饮料。所述功能保健饮料含有活性成份ω‑3脂肪酸、胆碱和尿苷组合物,所述的功能保健饮料还可以包含有甜菊糖,所述的ω‑3脂肪酸为十八碳三烯酸,二十二碳六烯酸,二十碳五烯酸,所述的胆碱为甘磷酸胆碱、氯化胆碱,所述的尿苷组合物为尿苷、脱氧尿苷、去氧氟尿苷和尿苷三磷酸,所述的十八碳三烯酸,二十二碳六烯酸,二十碳五烯酸的比例为质量比1:1~3:3~5,所述的甘磷酸胆碱、氯化胆碱的比例为质量比1~5:1,所述的功能保健饮料还含有维生素A、维生素B1、维生素B2、维生素B6、维生素B12、维生素C、维生素D、维生素E、维生素K2、维生素H和维生素P,所述的功能保健饮料还添加有微量元素。
Description
技术领域
本发明涉及保健食品技术领域,具体为一种预防和治疗痴呆的功能保健饮料。
背景技术
随着科学的发展,社会的进步,人的寿命逐渐增长,在加上饮食结构的调 整,高血压、高血脂、糖尿病的病人越来越多,五六十岁以后,患有脑萎縮、 痴呆的老年病人逐渐增多。这些老年人不喜和人交往,对亲人缺乏感情,情绪 急躁,易和人冲突,语言重复,多躁自私,对自己健康特别关心,责任感、荣 誉感、道德感不同程度减退,近事记忆力下降,理解、判断、计算力全面下降, 难胜任工作及家务,不能准确回答自己的姓名、年龄,最后口齿不清,言语杂 乱无章,卧床不起。
老年性痴呆是一种老年性神经系统退行性疾病。这种疾病表现为智能(大脑皮层的获得性高级机能)的全面衰退或损害。可以概括为:“一清楚;三损害;六降低”。一清楚是指意识清楚;三损害是指感觉机能损害,运动机能损害,思维机能损害;六降低是指记忆力降低,日常生活能力降低,语言能力降低,社会交往能力降低,担任社会职务能力降低,情感反应能力降低。这种疾病的特性是器质性、慢性、进行性和常见性。
老年性痴呆随着人口老龄化进程的加速,老年性痴呆患者越来越多。据报道痴呆患病率为:≥60岁(3%±);≥65岁(4%±);≥75-79岁(10%±);≥80-85岁(20%±)。目前全世界已有老年性痴呆病人2900万,中国的老年性痴呆患者已达到400万之多,按照中国老年化社会进程估算,预计在短短的10年时间里,中国老年人数将从2027年的3亿人迅速增加到2043年的4亿人。若按患病率3%计算,如不加以采取老年性痴呆病的积极预防措施到2027年老年性痴呆患者将会达到900万人以上。
老年性痴呆危害性极大,在发达国家,老年性痴呆已成为继心脏病、癌症、中风之后的第4位死亡原因,该病一旦确诊,男性平均存活时间为2-6年,女性为2-3年。从疾病第一症象出现开始,多在4-5年内死亡。这种病使老年人致残最严重;影响老年人生活质量最严重;增加家庭和社会负担最严重。而且这种病治疗难度大,至今医学界对该病的因果关系尚未搞清;疾病呈进行性进展;早期难以发现,中、晚期虽然容易发现,但是此时治疗已无望。
所以,提供一种同时具有预防和治疗痴呆的保健食品成为我们要解决的问题。
发明内容
本发明的目的在于提供一种预防和治疗痴呆的功能保健饮料,以解决上述背景技术中的问题。为实现上述目的,提供如下技术方案:
一种预防和治疗痴呆的功能保健饮料,所述功能保健饮料含有活性成份ω-3脂肪酸、胆碱和尿苷组合物。
优选的,所述的功能保健饮料还可以包含有甜菊糖
优选的,所述的ω-3脂肪酸为十八碳三烯酸,二十二碳六烯酸,二十碳五烯酸。
优选的,所述的胆碱为甘磷酸胆碱、氯化胆碱。
优选的,所述的尿苷组合物为尿苷、脱氧尿苷、去氧氟尿苷和尿苷三磷酸。
优选的,所述的十八碳三烯酸,二十二碳六烯酸,二十碳五烯酸的比例为质量比1:1~3:3~5。
优选的,所述的甘磷酸胆碱、氯化胆碱的比例为质量比1~5:1。
优选的,所述的功能保健饮料还含有维生素A、维生素B1、维生素B2、维生素B6、维生素B12、维生素C、维生素D、维生素E、维生素K2、维生素H和维生素P。
优选的,所述的功能保健饮料还添加有微量元素钙、铁、磷、锌、硒、钒、锶、钼。
优选的,所述的微量元素均以氨基酸盐的形式存在。
优选的,所述痴呆是选自于由阿尔茨海默病、血管性痴呆或轻度认知障碍(MCI)所组成的组中的任一种。
优选的,所述的尿苷、脱氧尿苷、去氧氟尿苷和尿苷三磷酸比例为质量比1:0.2~0.5:1~2:1~4。
优选的,所述的ω-3脂肪酸、胆碱、尿苷组合物、维生素和微量元素的比例为质量比100-500:10~50:10~100:1~10:1~5。
本发明的有益效果是:本发明可以对于阿尔茨海默病、血管性痴呆或轻度认知障碍等疾病有良好的预防和治疗作用。
具体实施方式
下面将结合本发明实施例对本发明实施例中的技术方案进行清楚、完整地描述,显然,所描述的实施例仅仅是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。
实施例一
一种预防和治疗痴呆的功能保健饮料,所述功能保健饮料含有活性成份ω-3脂肪酸、胆碱和尿苷组合物;所述的功能保健饮料还包含有甜菊糖;所述的功能保健饮料还含有维生素和微量元素;所述的ω-3脂肪酸、胆碱、尿苷组合物、维生素和微量元素的比例为质量比100-500:10~50:10~100:1~10:1~5;所述的ω-3脂肪酸为十八碳三烯酸,二十二碳六烯酸,二十碳五烯酸;所述的十八碳三烯酸,二十二碳六烯酸,二十碳五烯酸的比例为质量比1:1~3:3~5;所述的胆碱为甘磷酸胆碱、氯化胆碱;所述的甘磷酸胆碱、氯化胆碱的比例为质量比1~5:1;所述的尿苷组合物为尿苷、脱氧尿苷、去氧氟尿苷和尿苷三磷酸;所述的尿苷、脱氧尿苷、去氧氟尿苷和尿苷三磷酸比例为质量比1:0.2~0.5:1~2:1~4;所述的功能保健饮料还含有维生素A、维生素B1、维生素B2、维生素B6、维生素B12、维生素C、维生素D、维生素E、维生素K2、维生素H和维生素P;所述的功能保健饮料还添加有微量元素钙、铁、磷、锌、硒、钒、锶、钼;所述的微量元素均以氨基酸盐的形式存在;所述痴呆是选自于由阿尔茨海默病、血管性痴呆或轻度认知障碍(MCI)所组成的组中的任一种。
实施例二
一种预防和治疗痴呆的功能保健饮料,所述功能保健饮料含有活性成份ω-3脂肪酸、胆碱和尿苷组合物;所述的功能保健饮料无糖;所述的功能保健饮料还含有维生素和微量元素;所述的ω-3脂肪酸、胆碱、尿苷组合物、维生素和微量元素的比例为质量比200-400:20~30:30~50:1~5:1~3;所述的ω-3脂肪酸为十八碳三烯酸,二十二碳六烯酸,二十碳五烯酸;所述的十八碳三烯酸,二十二碳六烯酸,二十碳五烯酸的比例为质量比1:1~2:3~4;所述的胆碱为甘磷酸胆碱、氯化胆碱;所述的甘磷酸胆碱、氯化胆碱的比例为质量比2~5:1;所述的尿苷组合物为尿苷、脱氧尿苷、去氧氟尿苷和尿苷三磷酸;所述的尿苷、脱氧尿苷、去氧氟尿苷和尿苷三磷酸比例为质量比1:0.3~0.5:1~2:1~2;所述的功能保健饮料还含有维生素A、维生素B1、维生素B2、维生素B6、维生素B12、维生素C、维生素D、维生素E、维生素K2、维生素H和维生素P;所述的维生素A、维生素B1、维生素B2、维生素B6、维生素B12、维生素C、维生素D、维生素E、维生素K2、维生素H和维生素P的质量比为0.5份维生素A、1份维生素B1、1份维生素B2、1份维生素B6、0.6份维生素B12、3份维生素C、0.5份维生素D、0.7份维生素E、0.6份维生素K2、0.6份维生素H和0.05份维生素P;所述的功能保健饮料还添加有微量元素钙、铁、磷、锌、硒、钒、锶、钼;所述的微量元素钙、铁、磷、锌、硒、钒、锶、钼的比例为质量比为5钙、4铁、2磷、1锌、0.5硒、5钒、0.3锶、0.5钼;所述的微量元素均以氨基酸盐的形式存在;所述痴呆是选自于由阿尔茨海默病、血管性痴呆或轻度认知障碍(MCI)所组成的组中的任一种。
实施例三
一种预防和治疗痴呆的功能保健饮料,所述功能保健饮料含有活性成份ω-3脂肪酸、胆碱和尿苷组合物;所述的功能保健饮料还可以包含有甜菊糖,所述的功能保健饮料还含有维生素和微量元素;所述的ω-3脂肪酸、胆碱、尿苷组合物、维生素和微量元素的比例为质量比300:25:40:5:1;所述的ω-3脂肪酸为十八碳三烯酸,二十二碳六烯酸,二十碳五烯酸;所述的十八碳三烯酸,二十二碳六烯酸,二十碳五烯酸的比例为质量比1:1:3;所述的胆碱为甘磷酸胆碱、氯化胆碱;所述的甘磷酸胆碱、氯化胆碱的比例为质量比3:1;所述的尿苷组合物为尿苷、脱氧尿苷、去氧氟尿苷和尿苷三磷酸;所述的尿苷、脱氧尿苷、去氧氟尿苷和尿苷三磷酸比例为质量比1:0.4:1.5:2;所述的功能保健饮料还含有维生素A、维生素B1、维生素B2、维生素B6、维生素B12、维生素C、维生素D、维生素E、维生素K2、维生素H和维生素P;所述的维生素A、维生素B1、维生素B2、维生素B6、维生素B12、维生素C、维生素D、维生素E、维生素K2、维生素H和维生素P的质量比为0.6份维生素A、2份维生素B1、1份维生素B2、0.5份维生素B6、0.3份维生素B12、5份维生素C、0.1份维生素D、0.4份维生素E、0.2份维生素K2、0.3份维生素H和0.01份维生素P;所述的功能保健饮料还添加有微量元素钙、铁、磷、锌、硒、钒、锶、钼;所述的微量元素钙、铁、磷、锌、硒、钒、锶、钼的比例为质量比为3份钙、2份铁、2份磷、1份锌、0.5份硒、3份钒、0.2份锶、0.5份钼;所述的微量元素均以氨基酸盐的形式存在;所述痴呆是选自于由阿尔茨海默病、血管性痴呆或轻度认知障碍(MCI)所组成的组中的任一种。
实验发现服用本发明的功能保健饮料12月后,痴呆患者认知能力衰退减少了55%。患者脑部核磁共振(MRI)扫描结果显示,他们的大脑海马体萎缩程度也减少了35%,说明本发明对于治疗和延缓病情进展疗效显著。
样本调查发现,对于两组分别由200位65岁以上老人的组成的A组和B组,服用本发明的功能保健饮料的A组中,12月后,发生痴呆的人数仅为2人,而不服用的B组中,痴呆的发生人数为10人,说明本发明对于老年痴呆的发生可以起到显著的预防作用。
尽管参照前述实施例对本发明进行了详细的说明,对于本领域的技术人员来说,其依然可以对前述各实施例所记载的技术方案进行修改,或者对其中部分技术特征进行等同替换,凡在本发明的精神和原则之内,所作的任何修改、等同替换、改进等,均应包含在本发明的保护范围之内。
Claims (10)
1.一种预防和治疗痴呆的功能保健饮料,所述功能保健饮料含有活性成份ω-3脂肪酸、胆碱和尿苷组合物,所述的功能保健饮料还可以包含有甜菊糖。
2.根据权利要求1所述的一种预防和治疗痴呆的功能保健饮料,其特征在于,所述的ω-3脂肪酸为十八碳三烯酸,二十二碳六烯酸,二十碳五烯酸。
3.根据权利要求1所述的一种预防和治疗痴呆的功能保健饮料,其特征在于,所述的胆碱为甘磷酸胆碱、氯化胆碱。
4.根据权利要求1所述的一种预防和治疗痴呆的功能保健饮料,其特征在于,所述的尿苷组合物为尿苷、脱氧尿苷、去氧氟尿苷和尿苷三磷酸。
5.根据权利要求2所述的一种预防和治疗痴呆的功能保健饮料,其特征在于,所述的十八碳三烯酸,二十二碳六烯酸,二十碳五烯酸的比例为质量比1:1~3:3~5。
6.根据权利要求3所述的一种预防和治疗痴呆的功能保健饮料,其特征在于,所述的甘磷酸胆碱、氯化胆碱的比例为质量比1~5:1。
7.根据权利要求1所述的一种预防和治疗痴呆的功能保健饮料,其特征在于,所述的功能保健饮料还含有维生素A、维生素B1、维生素B2、维生素B6、维生素B12、维生素C、维生素D、维生素E、维生素K2、维生素H和维生素P。
8.根据权利要求1所述的一种预防和治疗痴呆的功能保健饮料,其特征在于,所述的功能保健饮料还添加有微量元素钙、铁、磷、锌、硒、钒、锶、钼。
9.根据权利要求8所述的一种预防和治疗痴呆的功能保健饮料,其特征在于,所述的微量元素均以氨基酸盐的形式存在。
10.根据权利要求1所述的一种预防和治疗痴呆的功能保健饮料,其中,所述痴呆是选自于由阿尔茨海默病、血管性痴呆或轻度认知障碍(MCI)所组成的组中的任一种。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201711149396.6A CN107889992A (zh) | 2017-11-18 | 2017-11-18 | 一种预防和治疗痴呆的功能保健饮料 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201711149396.6A CN107889992A (zh) | 2017-11-18 | 2017-11-18 | 一种预防和治疗痴呆的功能保健饮料 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN107889992A true CN107889992A (zh) | 2018-04-10 |
Family
ID=61805471
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201711149396.6A Pending CN107889992A (zh) | 2017-11-18 | 2017-11-18 | 一种预防和治疗痴呆的功能保健饮料 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107889992A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024003385A1 (en) | 2022-07-01 | 2024-01-04 | N.V. Nutricia | Nutritional composition for neurodegeneration and neurotrauma |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1232697A (zh) * | 1999-03-09 | 1999-10-27 | 李胤良 | 改善记忆、预防老年痴呆保健饮料 |
CN103495041A (zh) * | 2013-09-09 | 2014-01-08 | 崔书克 | 治疗老年性痴呆的补气活血饮 |
CN104039318A (zh) * | 2011-10-31 | 2014-09-10 | N·V·努特里奇亚 | 改善认知 |
CN105767829A (zh) * | 2016-04-25 | 2016-07-20 | 山东福田药业有限公司 | 一种改善大脑认知能力的功能饮料及制备方法 |
CN107252025A (zh) * | 2017-04-28 | 2017-10-17 | 深圳大学 | 一种预防老年痴呆的固体饮料 |
-
2017
- 2017-11-18 CN CN201711149396.6A patent/CN107889992A/zh active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1232697A (zh) * | 1999-03-09 | 1999-10-27 | 李胤良 | 改善记忆、预防老年痴呆保健饮料 |
CN104039318A (zh) * | 2011-10-31 | 2014-09-10 | N·V·努特里奇亚 | 改善认知 |
CN103495041A (zh) * | 2013-09-09 | 2014-01-08 | 崔书克 | 治疗老年性痴呆的补气活血饮 |
CN105767829A (zh) * | 2016-04-25 | 2016-07-20 | 山东福田药业有限公司 | 一种改善大脑认知能力的功能饮料及制备方法 |
CN107252025A (zh) * | 2017-04-28 | 2017-10-17 | 深圳大学 | 一种预防老年痴呆的固体饮料 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024003385A1 (en) | 2022-07-01 | 2024-01-04 | N.V. Nutricia | Nutritional composition for neurodegeneration and neurotrauma |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101087972B1 (ko) | 치매, 치매관련 질환의 예방/치료 및 인지기능장애 개선에 효과가 있는 유산균 발효 산물, 이의 제조방법 및 용도 | |
CN102450618B (zh) | 一种黑蒜的制作方法 | |
KR20190039987A (ko) | 주요 우울 장애의 치료용 조성물 | |
US20210330686A1 (en) | Composition containing 2'-fucosyllactose for preventing stroke | |
Cassisi et al. | Complementary and alternative medicine in fibromyalgia: a practical clinical debate of agreements and contrasts | |
TW201713330A (zh) | 肌肉脂肪化抑制用組成物 | |
EP1435971B1 (de) | Verwendung von phosphatidylserin zur behandlung des aufmerksamkeits-defizit-syndroms (adhs) | |
CN107889992A (zh) | 一种预防和治疗痴呆的功能保健饮料 | |
Kularatne et al. | Routine antibiotic therapy in the management of the local inflammatory swelling in venomous snakebites: results of a placebo-controlled study | |
WO2011002168A2 (ko) | 신규한 락토바실루스 헬베티쿠스 또는 이의 배양물의 치매 또는 인지기능장애 예방 또는 치료를 위한 용도 | |
CN107320674B (zh) | 一种改善认知、延缓痴呆病情进展的中药组合物及其应用 | |
EP3727407A1 (en) | Composition for use in the treatment and/or improvement of sleep and mood disorders | |
Roulet et al. | Delusional parasitosis treated by atypical antipsychotic and selective serotonin reuptake inhibitor: a case report | |
RU2400235C1 (ru) | Способ лечения больных с дисбактериозом кишечника | |
Joffe et al. | Effects of carbamazepine on serum electrolytes in affectively ill patients | |
DE60109651T2 (de) | Carnitin und huperzin enthaltende zusammensetzungen zur behandlung und vorbeugung von hyperaktivität mit aufmerksamkeitstörungen bei kindern | |
Ingham et al. | Thyroid psychosis: difficulties in diagnosis | |
Kashi et al. | Evaluation of the effect of jaw relaxation on sleep quality in patients with myocardial infarction | |
EP3426236B1 (en) | Method for supporting memory function and/or cognitive function | |
McLoughlin et al. | Lipid-lowering drugs | |
Singh et al. | Clinical evaluation of rasayana effect of madhuyashti churna in apparently healthy individuals | |
US20240115590A1 (en) | Compositions and therapeutic methods for treating chronic sequalae following viral infections | |
DE3814047C1 (en) | Composition for the treatment of multiple sclerosis | |
Yazdi et al. | Postoperative delirium in a patient following laparoscopi c cholecystectomy and spinal anesthesia | |
Grzebisz et al. | Health-promoting effects of Manuka honey |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180410 |
|
RJ01 | Rejection of invention patent application after publication |